Clareo Health | Comparing the TDTP-RECIST With RECIST 1.1 and Other Volumetric Evaluation Methods for Assessing the Therapeutic Efficacy of Irregular Malignant Tumors
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Shanghai Zhongshan Hospital
With
Shenzhen University General Hospital
Tianjin Cancer Hospital Airport Hospital
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Pathologically confirmed malignancy of one of the following types: biliary tract cancer (intrahepatic cholangiocarcinoma, hilar cholangiocarcinoma, or gallbladder cancer), breast cancer, or pancreatic ductal adenocarcinoma
2. Age 18 to 80 years (inclusive), any sex
3. Received neoadjuvant or conversion therapy before surgery; no prior anti-cancer therapy before that course
4. Underwent tumor surgical resection or biopsy after completion of neoadjuvant/conversion therapy
5. Available baseline and preoperative imaging with the same modality (contrast-enhanced CT or MRI) at both time points for response evaluation
6. Complete postoperative pathology report and follow-up data available
You may not be if
1. History of another malignancy or concurrent multiple primary cancers
2. Missing imaging or inconsistent imaging evaluation across time points (e.g., absent scans or differing modalities that preclude paired assessment)
